Highlights OncoZenge AB

Equities

ONCOZ

SE0015504097

Market Closed - Nasdaq Stockholm Other stock markets 16:29:54 23/05/2024 BST			5-day change	1st Jan Change
3.49 ^SEK	-2.92%		-5.93%	+12.94%

05-21	OncoZenge AB Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
04-08	Oncozenge AB Appoints Paolo Bossi as Member of the Advisory Board	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

OncoZenge AB Reports Earnings Results for the First Quarter Ended March 31, 2024	05-21	CI
OncoZenge Announces Read-Out of Positive Stability Data for BupiZenge	04-04	CI
OncoZenge AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	02-15	CI
OncoZenge Seeks to Expand Patent Protection for Oral Lozenge Product BupiZenge	02-07	MT
OncoZenge AB Files Patent Application for Strengthened IP Protection for BupiZenge	02-07	CI
OncoZenge Seeks Priority Medicines Status for Oral Pain Treatment in Europe	01-02	MT
Ensysce Biosciences and OncoZenge Announce Letter of Intent for the Co-Development of BupiZenge in the United States	11-28	CI
Oncozenge AB Confirms the New Formulation of Oncozenge's Drug Candidate Bupizenge?? Is Clean	11-21	CI
OncoZenge AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	31/10/23	CI
OncoZenge AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	31/08/23	CI
OncoZenge AB Reports Earnings Results for the First Quarter Ended March 31, 2023	16/05/23	CI
OncoZenge AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	14/02/23	CI
OncoZenge AB Reports Earnings Results for the Full Year Ended December 31, 2022	14/02/23	CI
OncoZenge AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	15/11/22	CI
OncoZenge AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	16/08/22	CI
OncoZenge AB Reports Earnings Results for the First Quarter Ended March 31, 2022	17/05/22	CI
OncoZenge AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2021	15/02/22	CI
OncoZenge AB Reports Earnings Results for the Full Year Ended December 31, 2021	15/02/22	CI
OncoZenge AB Initiates Toxicity Study and Announces Modification to the Clinical Plan	15/02/22	CI
ONCE : OncoZenge Receives Approval For Trading On Nasdaq Stockholm	10/02/21	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights OncoZenge AB

Equities

ONCOZ

SE0015504097

Highlights

Filters